Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc (SBFM) combines generic drug commercialization with cutting-edge research in oncology and antiviral therapies. This news hub provides investors and healthcare stakeholders with essential updates about the company's operational developments and scientific advancements.
Access timely press releases covering regulatory milestones, financial results, and research breakthroughs. Our curated collection includes updates on SBFM's generic drug portfolio through subsidiary Nora Pharma, plus progress reports on proprietary initiatives like the K1.1 mRNA-LNP cancer treatment and PLpro protease inhibitor program.
Key content categories include quarterly earnings announcements, partnership disclosures, clinical trial updates, and market expansion news. All materials are sourced directly from company communications to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to SBFM's latest developments. Regularly updated content helps stakeholders monitor both the company's established generics business and its innovative drug development pipeline in critical therapeutic areas.
Sunshine Biopharma (NASDAQ:SBFM) and the University of Arizona announced a new series of orally active, non‑covalent PLpro protease inhibitors that show dose‑dependent antiviral activity in mice infected with SARS‑CoV‑2. The compounds are potent against the PLpro enzyme, exhibited dose‑dependent efficacy in cellular SARS‑CoV‑2 models, and displayed favorable pharmacokinetic profiles in mice, rats and dogs. The program follows an initial PLpro library published in August 2024 in Journal of Medicinal Chemistry. Ongoing work includes dose‑dependent efficacy analysis in infected mice and further preclinical evaluation.
Sunshine Biopharma (NASDAQ:SBFM) has announced the launch of NIOPEG®, its first biosimilar drug, through its Canadian subsidiary Nora Pharma. NIOPEG® is comparable to NEULASTA® (Pegfilgrastim) and is designed to reduce infection risk in chemotherapy patients with non-myeloid malignancies.
The global market for NEULASTA® and its biosimilars was valued at $4.5 billion in 2024, with projections to reach $9.2 billion by 2033, growing at a CAGR of 8.5%. In Canada, where biologic drug sales reached $10 billion in 2020, the market represents a significant opportunity due to high per capita biologics spending and favorable provincial switching policies.
Sunshine Biopharma (NASDAQ:SBFM) has announced the launch of Everolimus, a generic oncology drug, in the Canadian market through its subsidiary Nora Pharma Inc. Everolimus, a generic equivalent of Afinitor®, is designed to treat multiple conditions including advanced renal cell carcinoma, HER2-negative breast cancer, neuroendocrine tumors, and subependymal giant cell astrocytoma.
The drug is available in 2.5 mg, 5 mg, and 10 mg strengths in 30-tablet blister packs. The global Everolimus market, valued at $2.5 billion in 2023, is projected to reach $4.8 billion by 2032 with a 7.1% CAGR. The Canadian market segment represents approximately 2.2% of the global market and is growing at a 6.4% CAGR.
Sunshine Biopharma (NASDAQ:SBFM) has successfully closed its previously announced registered direct offering, raising approximately $2.46 million through the sale of Common Stock and pre-funded warrants to institutional investors. The offering, priced at $2.07 per share, included 1,188,404 shares of Common Stock or Pre-Funded Warrants.
The Pre-Funded Warrants, priced at $2.06999 with an exercise price of $0.00001, are immediately exercisable. The transaction, which closed on April 3, 2025, was conducted under Nasdaq rules at market price. The company plans to utilize the net proceeds for general corporate purposes and working capital.
Aegis Capital Corp. served as the exclusive placement agent, with legal representation from various firms. The offering was executed through an effective shelf registration statement on Form S-3.
Sunshine Biopharma (NASDAQ:SBFM) has announced a $2.46 million registered direct offering with institutional investors, priced at $2.07 per share of Common Stock under Nasdaq rules. The offering includes 1,188,404 shares of Common Stock or Pre-Funded Warrants, with the latter priced at $2.069 with a $0.001 exercise price.
The Pre-Funded Warrants will be immediately exercisable until fully exercised. The transaction is expected to close around April 3, 2025, subject to customary conditions. The company plans to use the proceeds for general corporate purposes and working capital. Aegis Capital Corp is serving as the exclusive placement agent.
The offering is being conducted through an effective shelf registration statement on Form S-3, previously declared effective by the SEC on January 15, 2025.
Sunshine Biopharma (NASDAQ:SBFM) has announced positive results from studies of its K1.1 mRNA Lipid Nanoparticle (K1.1-mRNA-LNP) therapy for human hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths globally.
The company tested two versions of the treatment: a full-length mRNA (K1.1c) and a truncated version (K1.1d). Key findings include:
- The full-length K1.1c reduced growth of three different types of human HCC tumors in mice with good tolerability
- The truncated K1.1d showed significant anti-tumor activity in mouse HCC models in a dose-dependent manner
- Both versions were efficiently delivered to orthotopic engrafted HCC tumors through systemic administration
Additional animal studies are ongoing to determine optimal dosing of the truncated K1.1d version, which may offer better efficacy at lower doses compared to the full-length version.
Sunshine Biopharma (NASDAQ:SBFM) reported significant growth in fiscal 2024, with revenue reaching $34.9 million, marking a 45% increase from $24.1 million in 2023. Despite revenue growth, the company's net loss widened to $5.1 million from $4.5 million in 2023.
Key developments include:
- Completion of a $10 million public offering for sales operations expansion
- Launch of 13 new generic prescription drugs
- Health Canada approval for oncology drug NIOPEG®
- Publication of research on a new Coronavirus PLpro inhibitor
- Successful completion of mouse model studies for K1.1 mRNA Lipid Nanoparticle therapy for liver cancer treatment
The company's gross profit increased to $10.7 million, while general and administrative expenses rose to $16.5 million in 2024.
FAQ
What is the current stock price of Sunshine Biopharma (SBFM)?
What is the market cap of Sunshine Biopharma (SBFM)?
